TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04129931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: MCT Matching Placebo: MCT matching placebo packets. Mix 1-2 packets, as instructed by a physician, into liquid or food three times daily~Clazakizumab Matching Placebo: 12.5 mg subcutaneous saline injection given once every 4 weeks for 16 weeks.~Broncho-Vaxom Matching Placebo: 7 mg matching placebo taken orally once a day on an empty stomach for 16 weeks~Imatinib Matching Placebo: Two 100 mg placebo tablets orally once a day with a meal and an 8 oz glass of water for 2 weeks. Then four 100 mg placebo tablets once a day with a meal and an 8 oz glass of water for 14 weeks.~Cavosonstat Matching Placebo: 50 mg matching placebo capsule orally twice a day for 16 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: MCT Matching Placebo: MCT matching placebo packets. Mix 1-2 packets, as instructed by a physician, into liquid or food three times daily~Clazakizumab Matching Placebo: 12.5 mg subcutaneous saline injection given once every 4 weeks for 16 weeks.~Broncho-Vaxom Matching Placebo: 7 mg matching placebo taken orally once a day on an empty stomach for 16 weeks~Imatinib Matching Placebo: Two 100 mg placebo tablets orally once a day with a meal and an 8 oz glass of water for 2 weeks. Then four 100 mg placebo tablets once a day with a meal and an 8 oz glass of water for 14 weeks.~Cavosonstat Matching Placebo: 50 mg matching placebo capsule orally twice a day for 16 weeks.
Study: NCT03789864

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Biodynamic imaging (BDI) of mycosis fungoides
Description: Skin punch biopsy samples from cutaneous lesions will be profiled for sensitivity to gemcitabine using ex vivo Biodynamic imaging (BDI). A biodynamic profile, of either phenotypic responder or phenotypic non-responder, will be assigned.
Study: NCT00483067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-CdA
Description: 12 mg/m\^2/day by vein (IV) Continuous Infusion x 5 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: 1 gm/m\^2/day IV Over 2 Hours x 5 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF (Granulocyte colony-stimulating factor)
Description: 5 mcg/kg/day given under the skin (subcutaneously) starting Day 9
Study: NCT03011606

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic Surgery
Description: Robotic Surgery after Focal Ablation Therapy
Study: NCT03658213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZOLADEX 10.8 mg
Description: 10.8 mg depot for injection (equivalent to 10.8 mg goserelin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZOLADEX 3.6mg
Description: 3.6 mg depot for injection (equivalent to 3.6 mg goserelin)
Study: NCT00747942

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support for Increased Physical Activity
Description: Exercise referral combined with individual support, access to structured group exercise programs, and motivational support
Study: NCT00145379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tablet Metformin 500 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02063958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNX-5422
Description: Capsule dosed every other day for 21 days out of a 28 day cycle. Dose escalation based on safety not to exceed a dose of 100 mg/m2. Maintenance therapy of SNX-5422 at the MTD will be allowed for all patients not experiencing significant toxicity.
Study: NCT02711306

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucomannan noodle
Description: The participants received two servings (400 g) of GMN every day to replace their daily carbohydrate intake for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Glucomannan noodle
Description: The participants received two servings (400 g) of GMN every day to replace their daily carbohydrate intake for 4 weeks.
Study: NCT01256359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel and placebo
Description: Docetaxel 75mg/m2 IV and placebo given bd. Docetaxel will be administered every 3 weeks for a maximum 6 cycles, but placebo may be continued beyond this, until disease progression.
Study: NCT02505568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Participants will receive infliximab 5 milligram per kilogram (mg/kg) infusion at Week 0, Week 2, and Week 6 for the induction phase. Participants who complete the induction phase will continuously receive 5 mg/kg infliximab infusion every 8 weeks up to week 32 in the maintenance phase.
Study: NCT02624336

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DTC1
Description: 15ml DTC1 twice a day, rinse for 30sec refrain from eating or drinking for 30min
Study: NCT03960645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg FDC tablet administered orally once daily without regard to food.
Study: NCT03605420

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family visit prior to hospital admission
Description: Family receiving one visit prior to hospital admission for surgery
Study: NCT00647075

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yunzhi extract
Description: 3.5 g/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (starch)
Study: NCT02624336

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oradex
Description: 15ml Chlorhexidine gluconate 0.12% (w/v) twice a day, rinse for 30sec refrain from eating or drinking for 30min
Study: NCT03263117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sedation
Description: The protocol does not specify a particular combination of drugs that must be used for sedation.~The most common drugs utilized for sedation and wide dosing ranges are included in the protocol (i.e., sedation will be provided under the supervision of an anesthesiologist and may use a combination of fentanyl, midazolam, dexmedetomidine infusion (with or without loading dose), and/or low-dose propofol by intermittent bolus or infusion); however, the choice of specific drugs and dosages for achieving conscious sedation or general anesthesia will not be specified by the protocol but will be up to the anesthesiologist.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia (GA)
Description: The protocol doesn't specify drugs that must be used for GA, the choice of drugs and dosages for achieving general anesthesia will not be specified by the protocol but will be up to the anesthesiologist.~The most common drugs utilized for GA and wide dosing ranges included in the protocol are (GA will be provided under the supervision of an anesthesiologist and induction of anesthesia may be achieved with propofol and/or etomidate; muscle paralysis may be achieved with succinylcholine or non-depolarizing paralytic (rocuronium or vecuronium); and adjuvant lidocaine and fentanyl; if intravenous maintenance of anesthesia is used, it may be achieved by propofol infusion at 50 to 150 mcg/kg/min with redosing of non-depolarizing paralytic and fentanyl as needed; if inhalational maintenance of anesthesia is used it will be achieved with sevoflurane 1% to 2% or desflurane 3% to 6% end-tidal concentration with redosing of non-depolarizing paralytic and fentanyl as needed)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-arterial Thrombectomy
Description: The first line therapeutic embolectomy device should be a stent retriever. Additional Endovascular therapies including, but not limited to, intra- or extracranial angioplasty ± stenting; antithrombotics (oral, IV or IA antiplatelets or anticoagulants) intra-arterial thrombolytics; are left to the decision of the local treatment team.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-arterial Thrombectomy
Description: The first line therapeutic embolectomy device should be a stent retriever. Additional Endovascular therapies including, but not limited to, intra- or extracranial angioplasty ± stenting; antithrombotics (oral, IV or IA antiplatelets or anticoagulants) intra-arterial thrombolytics; are left to the decision of the local treatment team.
Study: NCT02711306

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo noodle
Description: In the placebo noodle diet, the participants received the same amount of noodles without glucomannan for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo noodle
Description: In the placebo noodle diet, the participants received the same amount of noodles without glucomannan for 4 weeks.
Study: NCT02624336

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water
Description: 15ml distilled water twice a day, rinse for 30sec refrain from eating or drinking for 30min
Study: NCT02728531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study: NCT02388750

Intervention type: DRUG
Group type: OTHER
Intervention: Palonosetron
Description: Palonosetron 0.5 mg every other day until completion of radiation and at least one hour prior on days of RT

Intervention type: DRUG
Group type: OTHER
Intervention: Palonosetron
Description: Palonosetron 0.5 mg every other day until completion of radiation and at least one hour prior on days of RT

Intervention type: RADIATION
Group type: OTHER
Intervention: Low or moderate risk radiotherapy
Description: Low or moderately emetogenic radiotherapy will be given to all patients on study.

Intervention type: RADIATION
Group type: OTHER
Intervention: Low or moderate risk radiotherapy
Description: Low or moderately emetogenic radiotherapy will be given to all patients on study.
Study: NCT01241643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT107
Description: repeated cycles of 3 injections of CYT107 at 20 µg/kg/week over 2 weeks, for a maximum of 4 cycles within 21 months and a maximum of 3 cycles within 12 months
Study: NCT00848172

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octanoic Acid
Description: 4mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical capsules
Study: NCT00977366

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochloric acid (0.15 molar)
Description: Hydrochloric acid (0.15 molar) will be infused in to the lower oesophagus through a distal infusion port located at the tip of an oesophageal stimulation catheter.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Normal saline will be infused in to the lower oesophagus through a distal infusion port located at the tip of an oesophageal stimulation catheter.
Study: NCT02934919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene
Description: 30 patients with ICDs, will be treated with 18 mg per day of nalmefene during 3 months
Study: NCT02728531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant
Study: NCT03134183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal Misoprostol
Description: Mifepristone 200mg orally 20-24 hours prior and misoprostol 400mcg (two 200mcg tablets) vaginally 1-2 hours prior and placebo (buccal mint powder) buccally 1-2 hours prior to D\&E

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buccal Misoprostol
Description: Mifepristone 200mg orally 20-24 hours prior and misoprostol 400mcg (two 200mcg tablets) ground with mint into buccal powder and placebo (two lactose tablets designed to appear similar to misoprostol) vaginally 1-2 hours prior to D\&E
Study: NCT02501369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-directed Teen Triple P
Description: Manualised parenting programme that parents will complete at home. This involves reading weekly modules of the manual and completing small exercises to practice the skills taught. These include strategies to help build positive relationships between parent and child, helping parents to effectively manage challenging childhood behaviours, and providing parents with the skills to support their child's independence and independent management of their cystic fibrosis.
Study: NCT04270032

Intervention type: DIAGNOSTIC_TEST
Intervention: ABUS and HHUS
Description: Using deep learning method to analyze and extract the features of automated breast ultrasound and hand-held ultrasound images

Intervention type: DIAGNOSTIC_TEST
Intervention: ABUS and HHUS
Description: Using deep learning method to analyze and extract the features of automated breast ultrasound and hand-held ultrasound images

Intervention type: DIAGNOSTIC_TEST
Intervention: ABUS and HHUS
Description: Using deep learning method to analyze and extract the features of automated breast ultrasound and hand-held ultrasound images
Study: NCT02748200

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiotherapy (EBRT)
Description: EBRT: 3 dose escalation levels

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiotherapy (EBRT)
Description: EBRT: 3 dose escalation levels

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiotherapy (EBRT)
Description: EBRT: 3 dose escalation levels
Study: NCT02234999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: 3mg \[14C\]-CC-122 will be administered as a single dose
Study: NCT00644306

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Thalidomide
Description: 100 mg/day continuously for 18 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: melphalan, prednisone
Description: 12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus placebo 100mg/d continuously for 18 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melphalan, prednisone, thalidomide
Description: 12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus thalidomide 100mg/d continuously for 18 months
Study: NCT03819543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Application of transcranial direct current stimulation via scalp electrodes over presumed epileptogenic focus for 20 minutes at 2.0 mA.
Study: NCT00758420

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varisolve (Polidocanol Endovenous Microfoam)
Description: 1% polidocanol, up to 15 mL, one treatment session (initially up to 30 ml, reduced to up to 15 ml in Amendment #2)
Study: NCT03105960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: garlic with lime mouth wash
Description: garlic with lime juice is herbal antimicrobial 10 ml (undiluted) for 30s and then expectorate for 14 days.o prepare garlic with lime mouth rinse, 100 g of fresh, washed garlic cloves was macerated in a sterile, ceramic mortar and water was added to obtain a homogenate which was then filtered off with a sterile muslin cloth. the final concentration of the solution was determined to be 1 g/100 ml. About 100 ml of lime juice was extracted from fresh lemons using a juice extractor and added to the garlic extract.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine
Description: hlorhexidine is antimicrobial, antiplaque mouthwash 10 ml (undiluted) for 30 second twice daily and then expectorate for 14 days.
Study: NCT01189552

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LETS ACT Behavioral Activation Treatment
Description: LETS ACT is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, \& Hopko, 2001). Treatment includes eight sessions over a four-week period and is provided in small group format, with each group consisting of 3-5 patients.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nondirective Therapy (NDT)
Description: The purpose of Nondirective Therapy (NDT) is to provide group therapy interaction, allowing for the development of a close therapeutic relationship and a safe and accepting environment to facilitate change. NDT will be conducted as outlined by Crits-Cristoph (1997). That is, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. Patients will received NDT in a small group format (3-5 participants) and will meet over the course of 4 weeks.
Study: NCT00047385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-dose helical computed tomography
Description: A LDCT is a computerized tomography image with low-dose technique without contrast. The scan is done from the neck to the diaphragm in one breath-hold.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: chest radiography
Description: The chest x-ray in this study was a single posterior-anterior film done with the participant upright.
Study: NCT03028805

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Automatic inclusion of COPD orders in admission orders
Description: Use of real-time data to identify a population of patients with COPD and prompt improved adherence to evidence-based guidelines through the automatic inclusion of a COPD order set in the admission orders.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Automatic inclusion of COPD orders in admission orders
Description: Use of real-time data to identify a population of patients with COPD and prompt improved adherence to evidence-based guidelines through the automatic inclusion of a COPD order set in the admission orders.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic, end-user order set design
Description: Use of a dynamic order set that has been end-user tested prior to launch rather than designed centrally by a committee to test use of order set components.
Study: NCT00758420

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Agitated Saline
Description: 10 u/mL normal heparinized saline solution, up to 20 mL, one treatment session
Study: NCT03274492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
Study: NCT03028805

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic, end-user order set design
Description: Use of a dynamic order set that has been end-user tested prior to launch rather than designed centrally by a committee to test use of order set components.
Study: NCT00308308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Insulin
Description: Inhalation, 15U/30U

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: sc injectable insulin
Study: NCT02194907

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain activity training - anterior insula
Description: training sessions using a special feedback technique to learn to actively increase blood flow in the front of the brain

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain activity training - medial prefrontal cortex
Description: training sessions using a special feedback technique to learn to actively increase blood flow in the back of the brain
Study: NCT01095848

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG
Description: Patients will receive three deep subcutaneous injections of the vaccine three weeks apart in the upper thigh region. Patients will be followed for up to 7 months.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG
Description: Patients will receive three deep subcutaneous injections of the vaccine three weeks apart in the upper thigh region. Patients will be followed for up to 7 months.
Study: NCT03274492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab IV infusion will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
Study: NCT01349998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Product 33525
Description: Daily dosing for 2 weeks each recurrence for patients with tinea pedis and Daily dosing for 1 week each recurrence for patients with tinea cruris and tinea corporis
Study: NCT02488798

Intervention type: PROCEDURE
Intervention: 2D grey scale vaginal ultrasound
Description: To assess the endometrial thickness and echogenicity (whether the endometrium is uniform or non-uniform).

Intervention type: PROCEDURE
Intervention: 3D power Doppler vaginal ultrasound
Description: To assess the endometrium using the IETA group criteria.
Study: NCT03045887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lactose as powder for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lactose as powder for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lactose as powder for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lactose as powder for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lactose as powder for inhalation
Study: NCT04219982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPI-386 Nasal Gel
Description: Nasal gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DPI-386 Placebo Nasal Gel
Description: DPI-386 Placebo Nasal Gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transderm Scop®
Description: Transderm Scop®
Study: NCT04011527

Intervention type: PROCEDURE
Intervention: Rotational Atherectomy in Coronary Lesion/s
Study: NCT02451228

Intervention type: OTHER
Intervention: Serial blood collection
Description: Serial blood collection from IV for pharmacokinetic and pharmacodynamic analysis. No drug, device, or biologic intervention. Opportunistic.
Study: NCT04518514

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAPE-Software
Description: Telemedical Risk Assessment and Preoperative Evaluation prior to anaesthesia via personal computer
Study: NCT00428896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD1839
Description: ZD1839 will be given at the dose of 250mg/day for a minimum of 3 months